PRTODAY / NewswireToday Free press release distribution service network

More news: Health/Surgery
Written by / Agency / Source: The Scott Partnership

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

PRECOS to Unveil New Pre-clinical Oncology Service Portfolio - Preclinical Oncology Services Limited (PRECOS), a leading pre-clinical research and development service provider with a specific focus on oncology - PRECOS.co.uk
PRECOS to Unveil New Pre-clinical Oncology Service Portfolio

 

NewswireToday - /newswire/ - Holmes Chapel, Cheshire, United Kingdom, 2012/02/02 - Preclinical Oncology Services Limited (PRECOS), a leading pre-clinical research and development service provider with a specific focus on oncology - PRECOS.co.uk.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Health/Surgery Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Preclinical Oncology Services Limited will be showcasing several new platforms for pre-clinical oncology research at two leading shows: Cancer Targets & Therapeutics, Las Vegas, February 27th - 28th and AACR, Chicago, March 31st - April 4th 2012.

PRECOS leads the way in providing robust models, validated against today’s Standard Of Care agents to enable pre-clinical in vitro and in vivo testing of the next generation of oncology candidate drugs. The International Agency for Research on Cancer (IARC) forecasts that by 2030 there will be over 26 million new cases and 17 million deaths per year from cancer. PRECOS will be launching several new cutting-edge services at the North American shows which support target validation and drug screening early in the research process for anti-cancer activity. The company provides expertise, specialism and innovation to small to medium biotechnology companies and the new platforms will support new and existing projects going forward.

At the shows PRECOS will highlight how it can deliver a customised screening platform either in 2-D or 3-D in vitro and/or in vivo that can far more closely model the development of cancer and therefore more accurately reflect the effect of potential candidate entities. Cell lines created from patient primary tissue that “never see plastic” are selected based their true characteristics as cancer cells, instead of their ability to survive in vitro.

Dr Neil Rotherham, chairman of PRECOS comments,“The new service lines demonstrate our commitment to offer a world-class service and the platforms provide significant benefits to clients. We are excited to talk to existing and potential clients from around the world at these leading events to demonstrate the breadth of solutions we can offer them for their oncology research and development needs.”

The 2012 3rd Cancer Targets & Therapeutics Conference examines new and emerging targets and therapeutics in the area of cancer research. Speakers at the event provide case studies of emerging targets in order to address some of the issues surrounding target-based drug discovery and development. The AACR Annual Meeting will highlight the best and latest findings in all major areas of cancer research. PRECOS’ full service offering will be highlighted at Cancer Targets & Therapeutics 2012 and on booth #4306 at AACR 2012. For further information please call +44 (0)870 166 6234, email enquiries[.]precos.co.uk or visit precos.co.uk.

About PRECOS Ltd
PRECOS Ltd (precos.co.uk) is a flexible pre-clinical research and development service with a specific focus on oncology, with an established track record in providing expert support to direct cancer drug development projects from concept to clinic. PRECOS evaluates the innovative cancer medicines of the future in patient-relevant models to ensure that pre-clinical efficacy assessment is predictive of how the drug is likely to behave in clinical trials with cancer patients. The PRECOS team of expert scientists assist in the selection and execution of appropriate analytical systems by a staged approach of in vitro studies, in vivo model development, subsequent in vivo mechanistic and therapeutic evaluations and post-study analyses, all conveyed with added value through specialist scientific interpretation of the data. PRECOS scientists apply cutting-edge technology and ideas to individual research programmes and delivers a flexible, tailored approach to all research objectives, whether a one-off service or a complete research programme.

PRECOS, an acronym of Pre-Clinical Oncology Services, was officially launched as a specialist business unit of the University of Nottingham (UK) in 2004. PRECOS evolved from the research expertise of the Division of Pre-clinical Oncology (formerly Academic Unit of Cancer Studies), which had successful collaborations with pharmaceutical and biotech companies in the UK, EU, US and Japan for over a decade.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Health/Surgery Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: The Scott Partnership

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 
 
  Your Banner Ad showing on ALL
Health/Surgery articles,
CATCH Visitors via Your Competitors Announcements!


PRECOS to Unveil New Pre-clinical Oncology Service Portfolio

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: ScottPR.com 
+44(0)14 7753 9539 precos[.]scottpr.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any The Scott Partnership securities in any jurisdiction including any other companies listed or named in this release.

Health/Surgery via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From The Scott Partnership / Company Profile


Read Health/Surgery Most Recent Related Newswires:

Sustainable Alternatives to Polyvinylidene Chloride-coated Films Create Growth Opportunities & Transform the Food Packaging Markets in Western Europe
RIKEN Biofunctional Synthetic Chemistry Laboratory in Japan Has Developed A Way to Engineer Glycan Complexes Clusters of Sugar Chains
The Clinicians of Longs Peak Emergency Physicians Join US Acute Care Solutions
Frost & Sullivan Recognizes BroadReach for Improving the Health and Wellbeing of Underserved Populations
Silver Spring Emergency Physicians Join US Acute Care Solutions
Stress Light Therapy Launches Crowd-Funded Campaign on Indiegogo.com
The Float Space - Brisbane's First Float and Cryo Therapy Centre to Open This November
Thought Leaders Across the Healthcare Spectrum to Participate in Industry-Wide Survey
Frost & Sullivan Names Optum 2016 North America Company of the Year for Population Health Management
R-Pharm Produces Biological Drugs in Yaroslavl with GE Healthcare's FlexFactory™ Manufacturing Platform
GE to Invest €150 Million in Biopharmaceutical Manufacturing Campus in Cork, Ireland, and Establish Advanced Manufacturing Training Centre At NIBRT
Moriarty Physical Therapy of the Hudson Valley Expands with New Office in Lagrange, NY
Ultimate Medical Group Announces A New Regenerative Medicine Division
Dr. Amir Hanna Introduces New Medical Innovation Taking the Pain Out of Physical Therapy
Samitivej Children’s Hospital Transforms its Sukhumvit Campus

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  NAKIVO, Inc.

Visit  JobsWare.com





 
  ©2016 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)